Pediatric Infectious Disease

Register      Login

VOLUME 3 , ISSUE 3 ( July-September, 2021 ) > List of Articles

Immunization Dialogue

Newer Vaccines for Tuberculosis Prevention

Sumitha Nayak

Keywords : BCG vaccine, Multidrug-resistant TB, Newer TB vaccines, Tuberculosis

Citation Information : Nayak S. Newer Vaccines for Tuberculosis Prevention. Pediatr Inf Dis 2021; 3 (3):121-124.

DOI: 10.5005/jp-journals-10081-1317

License: CC BY-NC 4.0

Published Online: 16-09-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

As per the latest data from World Health Organization, in the year 2019, a total of 10 million people fell ill with tuberculosis, of which 1.2 million were children, while 1.4 million people died due to tuberculosis. There are 30 high burden countries that are responsible for 87% of new TB cases. Eight countries account for two-thirds of the total, with India leading, followed by Indonesia, China, the Philippines, and four more countries. An important cog in the wheel of tuberculosis progression is the risk of TB infection progressing to TB disease. To break this wheel, active intervention is essential. A vaccine given to all children can help to confer protection, especially against severe disease forms. Currently, the role of the available BCG vaccine is limited to protection against disseminated TB and miliary TB. Currently, there are at least 15 candidate vaccines at different stages of clinical trials, while one vaccine has entered phase III. These newer vaccines have the potential of combating the disease as we forge ahead to end TB.


PDF Share
  1. World Health Organization, Tuberculosis. Key facts. Available at https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Accessed on 16.12.2020.
  2. World Health Organization, Global tuberculosis report 2020: executive summary. Available at: https://apps.who.int/iris/bitstream/handle/10665/337538/9789240016095-eng.pdf Accessed on 16.12.2020.
  3. Martin C. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? Eur Respir J 2005;26(1):162–167. DOI: 10.1183/09031936.05.00109904.
  4. Ahsan MJ. Recent advances in the development of vaccines for tuberculosis. Ther Adv Vaccines 2015;3(3):66–75. DOI: 10.1177/2051013615593891.
  5. World Health Organisation, Global Tuberculosis report 2020: executive summary. Available at https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf. Accessed on 28.4.2021.
  6. World Health Organisation, WHO preferred product characteristics for new tuberculosis vaccines. Available at https://apps.who.int/iris/bitstream/handle/10665/273089/WHO-IVB-18.06-eng.pdf?ua=1 Accessed on 28.4.2021.
  7. Martin C, Aguilo N, Marinova D, et al. Update on TB vaccine pipeline. Appl Sci 2020;10(7):2362. DOI: 10.3390/app10072632.
  8. ICMR, Need for effective TB Vaccines. Available at https://itrc.icmr.org.in//index.php/our-work/thematic-areas/vaccines. Accessed on 16.12.2020.
  9. Nieuwenhuizen NE, Kulkarni PS, Shaligram U, et al. The recombinant Bacille Calmette-Guerin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol 2017;8:1147. DOI: 10.3389/fimmu.2017.01147.
  10. Nieuwenhuizen NE, Kaufmann HES. Next generation vaccines based on Bacille Calmette-Guerin. Front Immunol 2018;9:121. DOI: 10.3389/fimmu.2018.00121.
  11. US National Library of Medicine. Clinical trials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT03152903. Accessed on 11 Feb2021.
  12. Bharathi K. Tuberculosis vaccine development: current status and future directions. J Clin Diagn Res 2019;13(9):AB01–AB04. DOI: 10.7860/JCDR/2019/17230.13164.
  13. Weerasuriya CK, Clark RA, White RG, et al. Review symposium. New tuberculosis vaccines: advances in clinical development and modelling. J Intern Med 2020;288(6):661–681. DOI: 10.1111/joim.13197.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.